Compare Charles River Laboratories Intl. Inc (CRL) vs FirstEnergy Corp. (FE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs FirstEnergy Corp. — how do they compare? Charles River Laboratories Intl. Inc trades at $299.21 (market cap $14.23B), while FirstEnergy Corp. trades at $44.9 (market cap $25.95B). The key difference: FirstEnergy Corp. is the larger of the two by market cap, and FirstEnergy Corp. pays a 4.15% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and FirstEnergy Corp. for 71 Days on average.
| CRL | FE | |
|---|---|---|
Market Cap | $14.23B | $25.95B |
Volume | 1,176,885 | 5,643,833 |
Sector | Health | Utilities |
52-Week High | $310.77 | $51.91 |
52-Week Low | $149.93 | $43.04 |
Typical Hold Time | 33 Days | 71 Days |
Enterprise Value | $17.06B | $54.87B |
Dividend Yield | — | 4.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
FirstEnergy (FE) trades at $44.58, up 0.72% with a bullish technical signal despite mixed earnings. The utility shows steady revenue growth to $15.09B in 2025 and maintains a 6.86% net margin, though recent quarters saw two EPS misses. Analyst consensus is Moderate Buy with a $52.80 target, while institutional interest grows with recent purchases by Nykredit and Corient Private Wealth.
FE offers stable utility operations with dividend support, but faces execution risks from its $36B Energize365 plan and rising debt. The stock's 8.4% upside to target and 4.2% dividend yield appeal to income investors, though high RSI suggests near-term pressure. Regulatory approvals and data-center demand are key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
